<DOC>
	<DOCNO>NCT02435277</DOCNO>
	<brief_summary>Study NS-0100-01E extension Study NS-01-0100 design assess safety long term effect ( i.e. , additional 8 week ) various fixed-dose leucine metformin combination ( NS-0100 ) versus standard metformin monotherapy glycemic control subject type 2 diabetes use HbA1c primary endpoint .</brief_summary>
	<brief_title>An Extension Protocol Evaluate Dose Comparisons Leucine-Metformin Combinations Type 2 Diabetic Patients</brief_title>
	<detailed_description>This randomize , 8-week , extension Study NS-0100-01 , evaluate effect various fixed-dose ( FDC ) combination leucine metformin compare standard metformin monotherapy glycemic control . Subjects meet inclusion criterion exclusion criterion extension study , include completion 4-week treatment period Study NS-0100-01 [ Day 28/Visit 7 ] ) , eligible enroll extension . During participation extension , subject continue receive assign treatment base upon randomization occur Day 1 ( Visit 4 ) Study NS-0100-0 . The study include total 3 visit : Visit 1E ( Day 28/Visit 7 Study NS-0100-01 ) , Visit 2E ( Day 56/Week 8 ) , Visit 3E ( Day 84/Week 12 ) . Key assessment Visit 2E Visit 3E include HbA1c , fast plasma glucose , plasma insulin . In addition , 3-hour standardized meal test perform Day 28 ( part Study Termination [ Visit 7 ] procedure Study NS-0100-01 prior enrol extension ) Study Termination extension ( Visit 3E [ Day 84/Week 12 ] ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Has complete Study NS010001 , include procedure require Study Termination ( Day 28/Visit 7 ) without major protocol deviation 2 . Is male , female , female , meet follow criterion : Not breastfeed Postmenopausal negative pregnancy test result ( human chorionic gonadotropin , beta subunit [ Î²hCG ] ) Screening ( Visit 1 ) ( require hysterectomized female ) If childbearing potential ( include perimenopausal woman menstrual period within one year ) sexually active , must practice willing continue practice appropriate birth control ( define method result low failure rate , i.e. , less 1 % per year , use consistently correctly , double barrier method [ male condom spermicide , without cervical cap diaphragm ] , implant , injectables , oral contraceptive [ must use least last 3 month ] , intrauterine contraceptive device , tubal ligation , vasectomized partner ) entire duration study . 3 . Is able read , understand , sign inform consent form ( ICF ) applicable , authorization use disclose protected health information form ( consistent health insurance portability accountability act 1996 [ HIPAA ] legislation ) , communicate investigator , understand comply protocol requirement . Subjects meet follow criterion exclude study . 1 . Is undesirable study participant judge investigator ( e.g. , exhibited poor compliance Study NS010001 ) 2 . Is expect require treatment , currently stable dose , change regimen follow medication : Lipidlowering agent Antihypertensive medication Thyroid replacement therapy Nonsteroidal antiinflammatory agent 3 . Is expect require undergo treatment follow medication : Antidiabetes medication ( exception study medication [ i.e. , metformin ] ) Oral parenteral steroid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Diabetes</keyword>
</DOC>